- Eckert & Ziegler SE has entered a strategic partnership with Bicycle Therapeutics to supply radioisotopes and manufacture Bicycle Radio Conjugates (BRC molecules).
- The collaboration will leverage Eckert & Ziegler’s GMP facility in Berlin to support Bicycle Therapeutics’ clinical trials in radiopharmaceuticals.
Eckert & Ziegler SE, a provider of isotope technology, has announced a strategic partnership with Bicycle Therapeutics, a pharmaceutical company developing Bicycle Radio Conjugates (BRC molecules). Under the agreement, Eckert & Ziegler will supply various radioisotopes and provide development and manufacturing services for Bicycle Therapeutics’ radiopharmaceutical pipeline.
Bicycle Therapeutics is advancing a novel class of therapeutics based on its proprietary bicyclic peptide technology. These molecules are designed for targeted delivery of therapeutic payloads, including radiopharmaceutical applications, to address unmet medical needs. Eckert & Ziegler’s Berlin-based GMP facility will play a central role in ensuring high-quality production and supply for clinical trials.
Dr. Harald Hasselmann, CEO of Eckert & Ziegler, commented on the collaboration: “We are delighted to enter into such a comprehensive partnership with Bicycle Therapeutics, whose innovative science is being used to develop promising radiopharmaceutical molecules.”
Bicycle Therapeutics plans to initiate its first radiopharmaceutical clinical trial next year. Mike Hannay, Chief Product and Supply Chain Officer at Bicycle Therapeutics, highlighted Eckert & Ziegler’s expertise in GMP-compliant manufacturing and global reach as key factors in selecting them as a manufacturing partner.
